急诊经皮冠状动脉介入术后心电图ST-T演变与预后的相关性被引量：2

下载PDF

导出

摘要 ST段抬高型心肌梗比(STEMI)由于冠状动脉心肌梗死急性闭塞使心肌严重受损,严重者出现心源性猝死,而当前开通闭塞血管最有效的治疗是实施急诊经皮冠状动脉介入术(PCI).心电图ST段回落及冠状动脉心肌梗死造影显示梗死血管血流再通是心肌再灌注的标志,与预后及梗死区室壁运动的恢复有明显的相关性[1].研究发现[2-4],STEMI患者行急诊PCI术后可改善心功能,可最大限度地缩小心肌梗死面积,使心肌收缩期和舒张期得以明显改善,提高广大患者的生活质量.

作者王全义

机构地区山西省汾阳医院心血管内科

出处《中国药物与临床》 CAS 2019年第10期1672-1673,共2页 Chinese Remedies & Clinics

关键词经皮冠状动脉介入术相关性心电图 ST-T 介入术后急诊预后心肌梗死面积

分类号 R542.22 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献4

1许骥,华琦,胡少东,刘志,李博宇,桑成,夏经钢.替格瑞洛在老年STEMI患者急诊PCI中的疗效与安全性分析[J].首都医科大学学报,2015,36(1):73-77. 被引量：78
2周恒,刘福元,骆峰,黎晓兰.冠状动脉使用替罗非班对STEMI患者急诊PCI术后的影响[J].临床心血管病杂志,2014,30(2):117-120. 被引量：17
3朱建兵,王瑾,周军,郭华,俞晓雯,张俊峰.替罗非班对急性STEMI患者安全性及近期预后的影响[J].中国循证心血管医学杂志,2014,6(1):40-43. 被引量：10
4梁鹍,董守仁,崔红营,彭欢.替格瑞洛在急性STEMI患者急诊PCI治疗中的疗效及安全性[J].中国临床研究,2014,27(8):937-939. 被引量：14

二级参考文献57

1中华医学会心血管病学分会介人心脏病学组,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南2012(简本)[J].中华心血管病杂志,2012,40(4):271-277.
2Kushner FG,Hand M,Smith SC Jr,et al. 2009 Focused Updates: ACC/ AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation,2009,120(22):2271-306.
3Lee DP,Herity NA,Hiatt BL,et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial[J]. Circulation, 2003, 107(I 1): 1497-501.
4Huber K,Holmes DR Jr,van't Hof AW,et al. Use of glycoprotein lib/ Ilia inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial[J]. Eur Heart J,2010,31 (14): 1708-16.
5Stone GW,Moliterno DJ,Bertrand M,et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial [J]. Circulation,2002,105(20):2347-54.
6Van't Hof AW,Ten Berg J,Heestermans T,et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a muhieentre, double- blind, randomised controlled trial[J]. Laneet,2008,372(9638):537-46.
7Moliterno DJ,Yakubov SJ,DiBattiste PM,et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during pereutaneous coronary revascularisation with stcnt placement: theTARGET follow-up study[J]. Lancet,2002,360(9330):355-60.
8Montalescot G,Borentain M,Payot L,et al. Early vs late administration of glycoprotein Hb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis[J]. JAMA,2004,292(3):362-6.
9Warnholtz A,Ostad MA,Heitzer T,et al. Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease[J]. Am J Cardiol,2005,95( 1):20-3.
10Boersma E,Harrington RA,Moliterno DJ,et al. Platelet glycoprotein IIb/lIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials[J]. Lancet,2002,359(9302):189-98.